obesity

Novo Nordisk’s Wegovy (semaglutide) Receives CHMP’s Recommendation for Approval to Treat Obesity

Shots: The EMA’s CHMP has adopted a positive opinion recommending the marketing authorization for Wegovy in adults with obesity in chronic weight management in adults with obesity The approval is based on P-IIIa (STEP) study evaluating Wegovy (2.4mg injection, qw) in ~4,500 adults with obesity or overweight with one weight-related comorbidity. The results showed 17-18% …

Novo Nordisk’s Wegovy (semaglutide) Receives CHMP’s Recommendation for Approval to Treat Obesity Read More »

Novo Nordisk nears EU approval of obesity drug Wegovy

Danish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU next year after getting a green light from the EMA’s human medicines committee. The CHMP recommended marketing authorisation for Wegovy (semaglutide) for chronic weight management in adults with obesity, and also in overweight adult patients with a …

Novo Nordisk nears EU approval of obesity drug Wegovy Read More »

Does Coconut Oil Help with Abdominal Fat?

What does a review of the evidence on the effects of coconut oil on weight loss and belly fat find?  I begin my video Flashback Friday: Coconut Oil and Abdominal Fat with a popular infographic that surprised me by showing that, evidently, there is promising evidence that coconut oil could help with obesity. Well, if you fill the stomachs of rats with purified medium-chain fatty acids, one component of coconut oil, they end …

Does Coconut Oil Help with Abdominal Fat? Read More »

Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity

Novartis was unsuccessful developing bimagrumab as a treatment for a rare muscle disorder, but additional tests showed encouraging results in fat reduction. Startup Versanis Bio licensed rights to the antibody and plans to use its Series A financing for clinical trials testing the drug in obese patients.

Diabetes Drug’s New Weight Loss Formula Fuels Cost-Benefit Debate

The long list of side effects that follow ads for the newer expensive drugs to treat Type 2 diabetes sometimes include an unusual warning: They might cause weight loss. That side effect is one that many people — especially those with Type 2 diabetes, which is associated with obesity — may desperately want. So it’s …

Diabetes Drug’s New Weight Loss Formula Fuels Cost-Benefit Debate Read More »

Regeneron, AZ team up on drugs for obesity “superpower” gene

AstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at GPR75, a protective gene identified by scientists at the Regeneron Genetics Centre. AZ’s buy into the programme comes a few weeks after Regeneron published findings in the journal Science suggesting that people with certain GPR75 mutations have …

Regeneron, AZ team up on drugs for obesity “superpower” gene Read More »

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity

Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated …

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity Read More »

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

Shots: The first patient has been dosed in a P-II clinical trial evaluating the efficacy and safety of IBI362 (GLP-1R and GCGR dual agonist) in a patient with overweight or obese in China The 1EPs of the study are to evaluate the change from baseline in body weight @24 wks., and to recommend the optimal …

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China Read More »

Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity

Shots: The approval is based on the results from the P-IIIa STEP clinical trial program evaluating Wegovy (2.4mg injection, qw) in ~4,500 adults with obesity or overweight with at least one weight-related comorbidity Results: the therapy showed 17-18% average weight loss in people without T2D @68wks. and has a safe and well-tolerated profile across the …

Novo Nordisk’s Wegovy (semaglutide, 2.4mg) Receives the US FDA’s Approval for Weight Management in Adults with Obesity Read More »

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicines.  Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – …

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy Read More »

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which it believes has the potential to redefine the market for weight-loss medicines.  Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation – which will be sold as Wegovy – …

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy Read More »

Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

Shots: The company reported the results from the P-IIIa STEP 1 trial of the STEP programme assessing semaglutide (2.4 mg, SC, qw) vs PBO in adults with obesity for 68 wks. The results will be presented at ECO 2021 Results: The therapy showed 14.9% weight loss, 43.8% improvement in total weight-related QoL scores, 51.2% vs …

Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity Read More »

Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity

Shots: The company plan to initiate a pivotal P-IIIa program to assess the efficacy and safety of oral semaglutide (50mg) vs PBO in ~1000 people with obesity or overweight with comorbidities for 68wks. The initiation follows the completion of the STEP P-IIIa clinical program with semaglutide (2.4mg, qw, SC). The study is expected to initiate …

Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity Read More »

Novo Nordisk Presents Results of Semaglutide in P-IIIa STEP 4 Trial to Treat Obesity at ENDO 2021

Shots: The P-IIIa STEP 4 trial involves assessing the safety and efficacy of Semaglutide (2.4 mg, SC, qw) vs PBO in adults with obesity for 68wks. The participants who reached the maintenance dose of semaglutide, during a 20wks. run-in period were randomized to either continue treatment with the therapy or switch to PBO for 48wks. …

Novo Nordisk Presents Results of Semaglutide in P-IIIa STEP 4 Trial to Treat Obesity at ENDO 2021 Read More »

How NLP Can Uncover Social Determinants of Heart Disease

David Talby, CTO, John Snow Labs Heart disease is the leading cause of death for people of most racial and ethnic groups in the United States. Cardiovascular disease-related deaths—which occur every 36 seconds—cost our country about $219 billion each year, according to the Centers for Disease Control and Prevention (CDC). People with poor cardiovascular health …

How NLP Can Uncover Social Determinants of Heart Disease Read More »

Glooko Raises $30M to Expand Digital Diabetes Management Platform

What You Should Know: – Glooko, a Palo Alto, CA-based provider of remote patient monitoring and chronic care management solutions including diabetes and obesity, today announced that they have raised a $30 million Series D round of funding. The funding was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, …

Glooko Raises $30M to Expand Digital Diabetes Management Platform Read More »

Are Lectins in Food Good or Bad for You?

Might lectins help explain why those who eat more beans and whole grains have less cancer? Lectins are to blame for the great “white kidney bean incident” of 2006 in Japan. One Saturday evening, a TV program introduced a new method to lose weight. The method was simple: toast some dry, raw, white kidney beans …

Are Lectins in Food Good or Bad for You? Read More »

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease

Jon Gingrich, CEO, Echosens North America Leveraging technological advances to facilitate new ways of engaging patients and integrating non-invasive technology into a liver disease program not only serves to improve individual outcomes and reduce costs but also strengthens the financial performance of health systems and provider organizations that include this approach to testing. At a …

Innovative, Non-Invasive Technologies Advanced Earlier Detection & Monitoring of Liver Disease Read More »

Pfizer vaccine may be less effective in people with obesity, says study

Healthcare workers with obesity found to produce only about half the antibodies healthy people do Coronavirus – latest updates See all our coronavirus coverage The Pfizer/BioNTech vaccine may be less effective in people with obesity, data suggests. Italian researchers have discovered that healthcare workers with obesity produced only about half the amount of antibodies in …

Pfizer vaccine may be less effective in people with obesity, says study Read More »

Novo Nordisk’s semaglutide effective against obesity in new trial

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the course of 15 months.  The trial involved 1,961 participants with a body-mass index of 30 or greater, and looked at the weekly GLP-1 …

Novo Nordisk’s semaglutide effective against obesity in new trial Read More »

DarioHealth Acquires Musculoskeletal Solution Upright for $31M

What You Should Know: – DarioHealth, a Livongo competitor acquires musculoskeletal startup Upright for $31 million to expand their chronic condition management capabilities focused on driving behavior change rather than treating the acute problem. This move will more than double revenue and create one of the largest integrated digital health companies in the space. In …

DarioHealth Acquires Musculoskeletal Solution Upright for $31M Read More »

Do the Pros of Brown Rice Outweigh the Cons of Arsenic?

Are there unique benefits to brown rice that would justify keeping it in our diet despite the arsenic content? For years, warnings had been given about the arsenic levels in U.S. rice potentially increasing cancer risk, but it had never been put to the test until a study out of Harvard. The finding? “Long-term consumption …

Do the Pros of Brown Rice Outweigh the Cons of Arsenic? Read More »

The Obesity Pandemic: What can we do about it?

Obesity today is a global crisis; the number of cases is on a continuous rise. As per the WHO,  “during the years 1975 to 2016, the prevalence of overweight or obese children and adolescents aged 5–19 years increased more than four-fold from 4% to 18% globally”. In 2016, more than 1.9 billion adults, 18 years …

The Obesity Pandemic: What can we do about it? Read More »

Humana Taps Vida Health to Power Virtual Diabetes Management for Kentucky’s Medicaid Population

What You Should Know: –  Humana Healthy Horizons™ in Kentucky announced it has selected Vida Health’s virtual diabetes management program to serve Kentucky’s Medicaid population. – Vida’s diabetes management program achieves lasting results for participants. Because chronic conditions like diabetes, obesity, and hypertension often occur simultaneously, Vida’s unique program was built from the ground up to …

Humana Taps Vida Health to Power Virtual Diabetes Management for Kentucky’s Medicaid Population Read More »

Digital Diabetes Market to Reach $1.5B by 2024, Research Finds

What You Should Know: – The digital diabetes market is on track to reach $1.5 billion dollars by 2024, according to a new report by Research2Guidance. – The confident growth of digital diabetes care will be driven by the growth of the global addressable market for digital diabetes services. Between 2019 and 2024, the number of diagnosed diabetics …

Digital Diabetes Market to Reach $1.5B by 2024, Research Finds Read More »

How Care Coordination Technology Addresses Social Isolation in Seniors

Jenifer Leaf Jaeger, MD, MPH, Senior Medical Director, HealthEC Senior isolation is a health risk that affects at least a quarter of seniors over 65. It has become recognized over the past decade as a risk factor for poor aging outcomes including cognitive decline, depression, anxiety, Alzheimer’s disease, obesity, hypertension, heart disease, impaired immune function, …

How Care Coordination Technology Addresses Social Isolation in Seniors Read More »

Price cut leads NICE to back Novo Nordisk’s obesity drug Saxenda

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management. The cost-effectiveness agency for England and Wales has recommended Saxenda (liraglutide) as a treatment option for people with a body mass index (BMI) of 35 or more, and who are also …

Price cut leads NICE to back Novo Nordisk’s obesity drug Saxenda Read More »

What White Blood Cell Count Should We Shoot for?

At the start of my video What Does a Low White Blood Cell Count Mean?, you can see what it looks like when you take a drop of blood, smear it between two pieces of glass, and view at it under a microscope: a whole bunch of little, round, red blood cells and a few …

What White Blood Cell Count Should We Shoot for? Read More »

No Purveyor of Unhealthy Products Wants the Public to Know the Truth

In 2011, Denmark introduced the world’s first tax on saturated fat. “After only 15 months, however, the fat tax was abolished,” due to massive pressure from farming and food company interests. “Public health advocates are weak in tackling the issues of corporate power…A well-used approach for alcohol, tobacco, and, more recently, food-related corporate interests is …

No Purveyor of Unhealthy Products Wants the Public to Know the Truth Read More »

Rural Hospital Execs Can Beat COVID-19 By Shifting From Reactive to Proactive Care

Eric Tran, Tulane School of Medicine Donald Voltz, MD, Aultman Hospital The COVID-19 virus is ravaging the planet at a scale not seen since the infamous Spanish Flu of the early 1900s, inflicting immense devastation as the U.S. loses more than 200,000 lives and counting. According to CDC statistics, 94% of patient mortalities associated with …

Rural Hospital Execs Can Beat COVID-19 By Shifting From Reactive to Proactive Care Read More »

How to Treat Polycystic Ovary Syndrome (PCOS) with Diet

Given the role that oxidant free radicals are thought to play in aging and disease, one reason fruits and vegetables may be so good for us is that they contain antioxidant compounds. As you can see at 0:20 in my video Benefits of Marjoram for Polycystic Ovary Syndrome (PCOS), different vegetables and herbs have different …

How to Treat Polycystic Ovary Syndrome (PCOS) with Diet Read More »

Virta Expands Offerings to Treat New Group of Chronic Illnesses

What You Should Know: – Virta is expanding its suite of treatment options to include prediabetes reversal, obesity reversal, and type 2 diabetes management. – By making this crucial expansion, Virta can scale its treatment to support the tens of millions of additional patients with prediabetes and obesity, as provide an on-ramp to reversal for …

Virta Expands Offerings to Treat New Group of Chronic Illnesses Read More »

Accounting for the Social Determinants of Health During the COVID-19 Pandemic

Andy Aroditis, CEO, NextGate The COVID-19 pandemic is not just a medical crisis.  Since the highly contagious disease hit American shores in early 2020, the virus has dramatically changed all sectors of society, negatively impacting everything from food supply chains and sporting events to the nation’s mental and behavioral health. For some people, work-from-home plans …

Accounting for the Social Determinants of Health During the COVID-19 Pandemic Read More »

4 Ways Businesses Will Adapt Their Healthcare Landscape

Dr. Donald Brown, CEO and founder of LifeOmic The coronavirus pandemic has affected every aspect of our lives, from how we work to how we get our health care. The crisis has put the creativity of many small businesses to the test after being forced to move operations online once social distancing became the norm. …

4 Ways Businesses Will Adapt Their Healthcare Landscape Read More »

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer

What You Should Know: The FDA and Syapse announce research collaboration expansion to address urgent public health challenges including supporting FDA’s goal of rapid understanding of COVID-19. As part of the research, Syapse is partnering with FDA’s Oncology Center of Excellence to investigate methods to derive RWD from multiple sources including electronic health records, registries …

FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer Read More »

Epidemia de obesidad en los Estados Unidos amenaza la eficacia de una vacuna contra COVID

Para un mundo paralizado por el coronavirus, la salvación depende de una vacuna. Pero en los Estados Unidos, en donde al menos 4,6 millones de personas se han infectado y casi 155,000 han muerto, la promesa de esa vacuna se ve obstaculizada por otra epidemia anterior a COVID-19: la de la obesidad. Los científicos saben …

Epidemia de obesidad en los Estados Unidos amenaza la eficacia de una vacuna contra COVID Read More »

America’s Obesity Epidemic Threatens Effectiveness of Any COVID Vaccine

For a world crippled by the coronavirus, salvation hinges on a vaccine. But in the United States, where at least 4.6 million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded COVID-19: obesity. Scientists know that vaccines engineered to protect the …

America’s Obesity Epidemic Threatens Effectiveness of Any COVID Vaccine Read More »

Merck & Co to repurpose failed obesity drug for NASH

Merck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson & Johnson, into a therapy for the fatty liver disease known as NASH. Non-alcoholic steatohepatitis, as the disease is also known, has been a target for pharma for years but is proving a tough nut to crack …

Merck & Co to repurpose failed obesity drug for NASH Read More »

The Crowding Out Strategy to Eating Healthier

It may be more expedient politically to promote an increase in consumption of healthy items rather than a decrease in consumption of unhealthy items, but it may be far less effective. The World Health Organization has estimated that more than a million deaths “worldwide are linked to low fruit and vegetable consumption.” What can be …

The Crowding Out Strategy to Eating Healthier Read More »

How to Foster a Healthy Gut Flora

What’s more important: probiotics or prebiotics? And where can we best get them? “Virtually every day we are all confronted with the activity of our intestine, and it is no surprise that at least some of us have developed a fascination for our intestinal condition and its relation to health and disease.” “Over the last …

How to Foster a Healthy Gut Flora Read More »